Cited 0 times in Scipus Cited Count

Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.

DC Field Value Language
dc.contributor.authorPark, JY-
dc.contributor.authorChung, YR-
dc.contributor.authorLee, K-
dc.contributor.authorSong, JH-
dc.contributor.authorLee, ES-
dc.date.accessioned2017-06-12T06:40:36Z-
dc.date.available2017-06-12T06:40:36Z-
dc.date.issued2015-
dc.identifier.issn0513-5796-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14119-
dc.description.abstractBehçet's disease (BD) involves multisystem vasculitis of unknown origin. Ocular manifestations of BD mostly include bilateral panuveitis and retinal vasculitis, which are very challenging to treat. Interferon alfa-2a (IFN) has been recently introduced for treating refractory Behçet uveitis, mainly in Germany and Turkey. Nonetheless, there is so far no consensus about the ideal treatment regimen of IFN for Behçet uveitis. We report our experience of IFN treatment in five Korean BD patients with refractory uveitis. All patients complained of oral ulcers; one patient had a positive pathergy test and 2 showed the presence of HLA-B51. Immunosuppressive agents used prior to IFN treatment included cyclosporine and methotrexate. The IFN treatment was commenced with a dose of 6-9 MIU/day for 7 days, adjusted according to individual ocular manifestations, tapered down to 3 MIU three times in a week, and then discontinued. All patients showed positive response to IFN treatment; 50% of them showed complete response without additional major ocular inflammation during the follow-up period. Other BD symptoms also improved after IFN treatment in most cases. After treatment, the relapse rate and the required dose of oral corticosteroid were decreased in most cases, showing a significant steroid-sparing effect. However, the visual acuity was not improved in most cases due to irreversible macular sequelae. Despite the small sample size of this study, we suggest that, in Korean patients, IFN is an effective treatment modality for BD uveitis as was observed in German and Turkish patients.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHBehcet Syndrome-
dc.subject.MESHChronic Disease-
dc.subject.MESHCyclosporine-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHImmunosuppressive Agents-
dc.subject.MESHInterferon-alpha-
dc.subject.MESHMale-
dc.subject.MESHRecombinant Proteins-
dc.subject.MESHRecurrence-
dc.subject.MESHRemission Induction-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTurkey-
dc.subject.MESHUveitis-
dc.subject.MESHVisual Acuity-
dc.titleClinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.-
dc.typeArticle-
dc.identifier.pmid26069144-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479849/-
dc.contributor.affiliatedAuthor정, 유리-
dc.contributor.affiliatedAuthor이, 기황-
dc.contributor.affiliatedAuthor송, 지훈-
dc.contributor.affiliatedAuthor이, 은소-
dc.type.localJournal Papers-
dc.identifier.doi10.3349/ymj.2015.56.4.1158-
dc.citation.titleYonsei medical journal-
dc.citation.volume56-
dc.citation.number4-
dc.citation.date2015-
dc.citation.startPage1158-
dc.citation.endPage1162-
dc.identifier.bibliographicCitationYonsei medical journal, 56(4). : 1158-1162, 2015-
dc.identifier.eissn1976-2437-
dc.relation.journalidJ005135796-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Ophthalmology
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
Files in This Item:
26069144.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse